Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Inspire Trust Co. N.A.

Inspire Trust Co. N.A. lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 44.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,000 shares of the biopharmaceutical company's stock after selling 45,500 shares during the period. Inspire Trust Co. N.A.'s holdings in Bristol-Myers Squibb were worth $3,280,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BMY. Fairway Wealth LLC acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $28,000. Transce3nd LLC acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $28,000. Comprehensive Financial Planning Inc. PA acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $34,000. Tacita Capital Inc acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $39,000. Finally, M Holdings Securities Inc. acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $39,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.07% of the company's stock.

Bristol-Myers Squibb Stock Down 0.3%

Bristol-Myers Squibb stock traded down $0.15 during mid-day trading on Friday, reaching $46.88. 8,401,343 shares of the company's stock were exchanged, compared to its average volume of 13,150,161. The company has a market cap of $95.40 billion, a P/E ratio of -10.61, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The company has a fifty day moving average of $51.79 and a 200-day moving average of $55.71.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same period in the prior year, the business earned ($4.40) EPS. The firm's quarterly revenue was down 5.6% on a year-over-year basis. Sell-side analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently 92.88%.

Analysts Set New Price Targets

Several research firms have weighed in on BMY. UBS Group decreased their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Citigroup boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Finally, Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.